



# Marksans Pharma Ltd.

February 05, 2026

**BSE Limited**

Corporate Relation Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400001  
**Scrip Code: 524404**

**National Stock Exchange of India Limited**

Listing Department  
Exchange Plaza, C-1, Block - G  
Bandra-Kurla Complex  
Bandra (East), Mumbai - 400051  
**Symbol: MARKSANS**

**Sub: Press Release**

Dear Sir/Madam,

Kindly find enclosed herewith a Press Release in relation to the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025.

Further, as per Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the said press release will also be available on the website of the Company i.e., <https://www.marksanspharma.com/press-release.html>.

We request you to take the aforesaid on record.

Thanking you.

Yours faithfully  
For **Marksans Pharma Limited**

Harshavardhan Panigrahi  
**Company Secretary**

Enclosed as above

## Marksans Pharma Ltd.

11<sup>th</sup> Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000

E-mail: [companysecretary@marksanspharma.com](mailto:companysecretary@marksanspharma.com)

[www.marksanspharma.com](http://www.marksanspharma.com)



## Q3 & 9MFY26 Financial Results

**Marksans Pharma delivered resilient performance in Q3FY26 with revenue growth of 10.6% YoY and EBITDA margin expansion of 217 bps YoY**

**Mumbai, February 5, 2026** – Marksans Pharma Ltd. (NSE: MARKSANS; BSE Code: 524404) reported the financial results today for the quarter and nine months ended December 31, 2025.

**Mark Saldanha, Managing Director of the Company, said,** *"We delivered a stable and resilient performance in Q3 FY26, with operating revenue growing 10.6% YoY, supported by steady execution across key markets and improved seasonal demand. Margins expanded sequentially, driven by soft raw material costs, favorable currency movements, and an improving product mix, while EBITDA growth reflected operating leverage.*

*During the quarter, we took measured steps to strengthen our global footprint through new subsidiaries in Europe and Canada, positioning the Company for long-term growth in regulated markets. We remain disciplined, execution-focused, and committed to delivering sustainable growth and long-term shareholder value."*

### Q3FY26 Financial Highlights

- Operating revenue stood at Rs. 754.4 cr., up by 10.6% YoY, attributed to strong traction in the US and UK markets, supported by robust momentum from new product launches and market share gains
- Gross profit stood at Rs. 438.2 cr., up by 14.3% YoY, with gross margin of 58.1%
- EBITDA stood at Rs. 160.7 cr.; EBITDA margin at 21.3%, expanded 217 bps YoY
- EPS was Rs. 2.5

### 9MFY26 Financial Highlights

- Operating revenue stood at Rs. 2,094.8 cr., up by 9.4% YoY
- Gross profit came in at Rs. 1,208.2 cr., up by 10.3% YoY, with a gross margin of 57.7%
- EBITDA stood at Rs. 405.4 cr.; EBITDA margin came in at 19.4%
- EPS was Rs. 6.0

### Business Highlights

#### US Market

- US & North America Formulation business reported revenues of Rs. 412.4 cr. in Q3FY26; performance in-line with expectation, driven by volumes supported by seasonal demand

### UK and Europe Market

- Revenues from the UK & Europe Formulation business in Q3FY26 stood at Rs. 258.2 cr.; growth driven by new launches and currency tailwinds

### Australia and New Zealand Market

- Australia and New Zealand businesses reported revenues of Rs. 61.4 cr. in Q3FY26

### RoW Market

- RoW business reported revenues of Rs. 22.4 cr. in Q3FY26

### Other Highlights

- **Cash generated from operations** at ₹ 263.2 cr during 9MFY26
- **Capex** of ₹ 97.0 cr incurred during 9MFY26
- **Working capital cycle** ~151 days for Q3FY26
- **Cash balance** of ₹ 824.2 cr as on 31<sup>st</sup> December 2025
- **Research & development (R&D)** spends at ₹ 62.0 cr in 9MFY26, 3.0% of consolidated revenue

## Business Performance

### Consolidated profit and loss statement:

Particulars	Q3FY26	Q3FY25	Q2FY26	YoY	QoQ	9MFY26	9MFY25	YoY
Operating Revenue	754.4	681.8	720.4	10.6%	4.7%	2,094.8	1,914.4	9.4%
Gross Profit	438.2	383.5	411.8	14.3%	6.4%	1,208.2	1,095.9	10.3%
<i>Gross margin</i>	<i>58.1%</i>	<i>56.2%</i>	<i>57.2%</i>	<i>184 bps</i>	<i>92 bps</i>	<i>57.7%</i>	<i>57.2%</i>	<i>43 bps</i>
EBITDA	160.7	130.5	144.5	23.2%	11.2%	405.4	405.7	-0.1%
<i>EBITDA Margin</i>	<i>21.3%</i>	<i>19.1%</i>	<i>20.1%</i>	<i>217 bps</i>	<i>125 bps</i>	<i>19.4%</i>	<i>21.2%</i>	<i>-184 bps</i>
PAT	113.7	105.1	99.1	8.2%	14.7%	271.0	291.9	-7.1%
<i>Net Margin</i>	<i>14.7%</i>	<i>14.6%</i>	<i>13.4%</i>	<i>4 bps</i>	<i>132 bps</i>	<i>12.7%</i>	<i>14.9%</i>	<i>-220 bps</i>
EPS (Rs.)	2.5	2.3	2.2	8.3%	15.2%	6.0	6.4	-7.0%

All figures in Rs. Cr. unless otherwise stated

Note: Net Income Margin = Net profit / Total Income (Revenue from operations + Other Income)

### Business-wise performance:

Particulars	Q3FY26	Q3FY25	YoY	Mix	9MFY26	9MFY25	YoY
US & North America	412.4	352.9	16.9%	54.7%	1,127.3	908.0	24.2%
UK and Europe	258.2	257.6	0.2%	34.2%	707.3	755.7	-6.4%
Australia & NZ	61.4	47.2	30.1%	8.1%	179.7	176.3	1.9%
Rest of World (ROW)	22.4	24.1	-7.2%	3.0%	80.6	74.3	8.4%
<b>Revenue from operations</b>	<b>754.4</b>	<b>681.8</b>	<b>10.6%</b>	<b>100%</b>	<b>2,094.8</b>	<b>1,914.4</b>	<b>9.4%</b>

All figures in Rs. Cr. unless otherwise stated

## Earnings Conference Call:

There will be an Earnings conference call at 4:00 pm IST on February 6, 2026, during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at [www.marksanspharma.com](http://www.marksanspharma.com).

Date and Time	February 6, 2026, at 4:00 pm IST
Diamond pass link	<a href="#">Link</a>
Primary Access Numbers	+91 22 6280 1384, +91 22 7115 8285
International Toll-Free Numbers	US: 18667462133 UK: 08081011573 Singapore: 8001012045 Hong Kong: 800964448

## About Marksans Pharma Ltd

Marksans Pharma Limited ([www.marksanspharma.com](http://www.marksanspharma.com)) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

## Disclaimer

Certain statements in this press release may contain forward-looking statements, including, but not limited to, statements regarding the Company's business strategies, operations, financial condition, and future performance. These forward-looking statements are based on current expectations, assumptions, and estimates, and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

### Contact Information

#### **Jitendra Sharma, CFO**

Marksans Pharma Ltd

Tel: +91 022 40012000

[jitendra@marksanspharma.com](mailto: jitendra@marksanspharma.com)

### Registered Office

11th Floor, "GRANDEUR"

Off Veera Desai Extension Road

Oshiwara, Andheri West

Mumbai, Maharashtra, 400 053

Telephone: +91 224001 2000

Fax: +91 224001 2011

CIN: L24110MH1992PLC066364

ISIN: INE750C01026

NSE Code: MARKSANS

BSE CODE: 524404

Website: <http://www.marksanspharma.com>